HIV-associated neurocognitive disorder

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir

Authors: Kevin Robertson, Paul Maruff, Lisa L. Ross, David Wohl, Catherine B Small, Howard Edelstein & Mark S. Shaefer

Journal: Journal of Neurovirology

Year Published: 2019

Human immunodeficiency virus (HIV)-associated neurocognitive disorders can persist in many patients despite achieving viral suppression while on antiretroviral therapy (ART). Neurocognitive function over 48 weeks was evaluated using a Cogstate test battery assessing psychomotor function, attention, […]

Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure

Authors: Jody Kamminga, Mark Bloch, Trina Vincent, Angela Carberry, Bruce J Brew, Lucette A Cysique

Journal: Journal of Clinical and Experimental Neuropsychology

Year Published: 2017

Introduction: The current study sought to determine the optimal impairment rating definition for a new HIV-associated neurocognitive disorder (HAND) screening procedure as compared to standard neuropsychological testing. Method: A total of 55 HIV-infected (HIV+; 19% AIDS; […]

Back to Publications